SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech fireworks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (2560)7/25/2006 9:51:16 AM
From: Saulamanca  Read Replies (1) of 7424
 
MNTA up another 30%

MNTA Momenta Pharma and Sandoz sign exclusive collaboration to develop complex generics and follow-on versions of biotechnology drugs

Co announces an exclusive collaboration with Sandoz, the generics business of Novartis (NVS), to develop four follow-on and complex generic versions of previously approved recombinant biotechnology and complex drugs. As part of the collaboration, Sandoz will make an initial payment of $75 mln to the co for the purchase of approx 4.7 mln shares at a price of $15.93 per share, a 30% premium to the trailing 30-day average. The co is also eligible to receive up to $188 mln in additional payments if all milestones are achieved for the four product candidates. The collaboration will include one late-stage compound from the co's pipeline and two late-stage compounds from Sandoz.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News